Illinois Tool Works Inc. vs Moderna, Inc. — how do they compare? Illinois Tool Works Inc. trades at $293.7 (market cap $83.49B), while Moderna, Inc. trades at $60.36 (market cap $24.18B). The key difference: Illinois Tool Works Inc. is far larger — about 3.5× Moderna, Inc.'s market cap, and Illinois Tool Works Inc. pays a 2.35% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| ITW | MRNA | |
|---|---|---|
Market Cap | $83.49B | $24.18B |
Sector | Industrials | Health |
52-Week High | $299.60 | $81.80 |
52-Week Low | $241.07 | $22.36 |
Enterprise Value | $92.34B | $20.33B |
Dividend Yield | 2.35% | — |
Signals from Pluang's Aura AI — not financial advice
ITW trades at $294.52, down 0.72% today, with bullish technical signals from moving averages and a consensus price target of $314.25 representing 6.7% upside. The company has beaten earnings estimates for three consecutive quarters, maintains strong profitability with 19.39% net margins, and recently announced a 7% dividend increase alongside a $6 billion share repurchase program. Revenue remains stable around $16 billion annually with consistent cash flow generation.
The outlook remains positive given strong operational execution and shareholder returns, though valuation multiples appear elevated with a P/E of 26.55. Key risks include potential margin pressure from economic cycles and high debt levels at 55.54% of assets. The stock offers quality exposure to industrial recovery with disciplined capital allocation.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Trailing returns across standard periods
Latest headlines on both assets
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →